The ultimate goal for the treatment of advanced cancer is significantly longer overall survival with the best possible quality of life for the patients. However, to date, no cyclin-dependent kinase 4/6 inhibitor had shown a significant overall survival benefit in patients with advanced breast cancer. 1 Ribociclib as a first-line or second-line endocrine treatment showed a significant overall survival benefit in patients with advanced hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 2 Reference: Slamon DJ, et al., New England Journal of Medicine, 2020 Feb 6;382(6):514-24.
Hindie E, New England Journal of Medicine, 2020 Jun 1;382(23):e85. Novartis and Docplexus have organized an Interactive Webinar on 5 th October 2020 from 04:30 pm onwards . In this webinar, Dr. Chanchal Goswami will share his opinion on the proven strategy for…
